ABN Amro Investment Solutions Has $12.26 Million Stock Position in Edwards Lifesciences Corporation $EW

ABN Amro Investment Solutions lifted its position in Edwards Lifesciences Corporation (NYSE:EW) by 526.7% during the 1st quarter, HoldingsChannel.com reports. The fund owned 153,031 shares of the medical research company’s stock after buying an additional 128,612 shares during the quarter. ABN Amro Investment Solutions’ holdings in Edwards Lifesciences were worth $12,255,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in EW. Mirae Asset Global Investments Co. Ltd. raised its stake in Edwards Lifesciences by 27.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock valued at $9,356,000 after purchasing an additional 23,514 shares during the period. Sivik Global Healthcare LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $2,984,000. Norges Bank acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $803,686,000. TD Asset Management Inc grew its holdings in shares of Edwards Lifesciences by 6.4% during the fourth quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock valued at $66,335,000 after buying an additional 47,051 shares in the last quarter. Finally, Intech Investment Management LLC grew its holdings in shares of Edwards Lifesciences by 22.2% during the fourth quarter. Intech Investment Management LLC now owns 69,347 shares of the medical research company’s stock valued at $5,912,000 after buying an additional 12,591 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares in the company, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 45,577 shares of company stock worth $3,855,527 over the last ninety days. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Down 0.2%

EW opened at $84.38 on Thursday. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The business has a 50-day moving average of $87.65 and a 200-day moving average of $83.90. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The company has a market capitalization of $48.59 billion, a PE ratio of 44.88, a price-to-earnings-growth ratio of 2.12 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.64 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Citigroup upped their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Royal Bank Of Canada lifted their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. BTIG Research upped their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Robert W. Baird increased their price target on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.